Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "MeiraGTx" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about MeiraGTx for you to read. Along with our medical data and news we also list MeiraGTx Clinical Trials, which are updated daily. BioPortfolio also has a large database of MeiraGTx Companies for you to search.
Johnson & Johnson’s Janssen Pharmaceutical Cos. will partner with MeiraGTX Holdings to develop, manufacture and commercialize its clinical-stage inherited retinal disease portfolio, the companies said today, through a global collaboration and license agreement that could generate more than $440 million for MeiraGTx. The collaboration—the second between the companies launched in the past th...
MeiraGTx's AAV-CNGA3, which is being developed for the treatment of achromatopsia caused by mutations in the CNGA3 gene, rece -More-
MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
eXmoor pharma and MeiraGTx are delighted to announce an extension to their strategic collaboration. eXmoor is providing process development services from its Commercialisation Laboratories at Future Space, Bristol. Two streams of work have focused on development of the MeiraGTx adherent and suspension cell process platforms and have demonstrated yield improvement as well as scale up towards commer...
MeiraGTx will use their riboswitch technology to engineer gene therapy constructs encoding gene sequences from Janssen
LONDON and NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph....
Johnson and Johnson subsidiary Janssen has entered into a collaboration and licence agreement with gene therapy company MeiraGTx for the...Read More... The post Janssen signs inherited retinal disease therapies deal with MeiraGTx appeared first on Pharmaceutical Technology.
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has established a new agreement with clinical-stage gene therapy company, MeiraGTx
MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop, The post Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs appeared first on Pharmaceutical Business review.
MeiraGTx's AAV-CNGA3, being developed to treat patients with achromatopsia due to mutations in the CNGA3 gene, was given rare -More-
While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the...
Janssen, the pharmaceuticals arm of Johnson & Johnson, is once again collaborating with US clinical-stage gene therapy company MeiraGTx to develop and commercialize treatments for inherited retinal diseases (IRDs).
MeiraGTx Holdings PLC and Janssen Pharmaceuticals Inc. are teaming up in the development and commercialization of gene therap...
MeiraGTx Holdings PLC and Janssen Pharmaceuticals Inc. are teaming up in the gene therapy space.
MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transacti...
MeiraGTx has announced a strategic collaboration with Johnson & Johnson’s Janssen to develop and commercialise gene therapy treatments for inherited retinal diseases (IRDs).
MeiraGTx Holdings PLC received exclusive global rights from the National Institutes of Health’s National Institute of Denta...
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Gene therapy has come of age over the past few years. And Johnson & Johnson this morning gave its biggest signal yet that it wants in on the emerging field. J&J (NYSE: JNJ) has inked a deal with MeiraGTX (NASDAQ: MGTX) to grab rights to a group of experimental gene therapies for inherited forms of […]
In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage gene therapy firm MeiraGTx Holdings with the goal of developing and marketing new treatments for inherited retinal diseases. Specifically, the collaboration hopes to look into developing leading candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X...
RARITAN, N.J., Jan. 31, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates...
. @JNJNews's @JanssenGlobal partners with @MeiraGTx on retinal disease #genetherapy: http://ow.ly/qjDW30nwNpi